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Abstract
We have previously identified NOD2 genotype and inflammatory bowel diseases (IBD) phe-
notype, as associated with shifts in the ileal microbiome (“dysbiosis”) in a patient cohort.
Here we report an integrative analysis of an expanded number of Crohn’s disease (CD)
related genetic defects in innate immune function (NOD2, ATG16L1, IRGM, CARD9, XBP1,
ORMDL3) and composition of the ileal microbiome by combining the initial patient cohort
(Batch 1, 2005–2010, n = 165) with a second consecutive patient cohort (Batch 2, 2010–
2012, n = 118). These combined patient cohorts were composed of three non-overlapping
phenotypes: 1.) 106 ileal CD subjects undergoing initial ileocolic resection for diseased
ileum, 2.) 88 IBD colitis subjects without ileal disease (predominantly ulcerative colitis but
also Crohn’s colitis and indeterminate colitis, and 3.) 89 non-IBD subjects. Significant differ-
ences (FDR < 0.05) in microbiota were observed between macroscopically disease unaf-
fected and affected regions of resected ileum in ileal CD patients. Accordingly, analysis of
the effects of genetic and clinical factors were restricted to disease unaffected regions of the
ileum. Beta-diversity differed across the three disease categories by PERMANOVA (p <
0.001), whereas no significant differences in alpha diversity were noted. Using negative
binomial models, we confirmed significant effects of IBD phenotype, C. difficile infection,
and NOD2 genotype on ileal dysbiosis in the expanded analysis. The relative abundance of
the Proteobacteria phylum was positively associated with ileal CD and colitis phenotypes,
but negatively associated with NOD2R genotype. Additional associations with ORMDL3 and
XBP1 were detected at the phylum/subphylum level. IBD medications, such as immuno-
modulators and anti-TNFα agents, may have a beneficial effect on reversing dysbiosis asso-
ciated with the IBD phenotype. Exploratory analysis comparing microbial composition of the
disease unaffected region of the resected ileum between 27 ileal CD patients who subse-
quently developed endoscopic recurrence within 6–12 months versus 34 patients who did
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not, suggested that microbial biomarkers in the resected specimen helped stratify patients
with respect to risk of post-surgical recurrence.
Introduction
Inflammatory bowel disease (IBD) describes a group of disorders in which the intestines
become inflamed. Two major types of IBD are ulcerative colitis (UC) and Crohn’s disease
(CD). UC is limited to the colon or large intestine. Crohn’s disease, on the other hand, can
involve any part of the gastrointestinal tract from the mouth to the anus. Most commonly,
though, it affects the ileum or the colon or both. Abnormal host-microbial interactions and
genetic susceptibility are implicated in the pathogenesis of IBD, reviewed in [1]. We previously
examined the effects of the NOD2 and ATG16L1 polymorphisms on ileal microbial composi-
tion in 1) ileal CD subjects undergoing initial ileal resection, 2) IBD colitis without ileitis (pre-
dominantly ulcerative colitis) subjects and 3) subjects without inflammatory bowel disease
(non-IBD) [2–4]. These previous studies identified NOD2 genotype and C. difficile infection,
in addition to IBD phenotype, as associated with shifts in ileal microbiota or “dysbiosis” [2–4].
We also found that differential expression of genes involved in Paneth cell function were asso-
ciated with shifts in ileal microbial composition [5]. In the current study, the effects of an
expanded panel of Crohn’s disease risk alleles [6–10] that are associated with defects in innate
immunity (NOD2, ATG16L1, IRGM, CARD9, XBP1, ORMDL3) on ileal microbial composi-
tion, were analyzed by combining the original patient cohort (referred to as “Batch 1 2005–
2010”) with a second consecutive patient cohort collected between 2010 and 2012 (“Batch 2
2010–2012”, see Table 1”) Some of these genes are implicated in autophagy (e.g. ATG16L1,
IRGM), or endoplasmic reticulum stress (e.g. XBP1, ORMDL3), and/or Paneth cell dysfunc-
tion (NOD2 ATG16L1, IRGM).
The majority of patients with the ileal CD phenotype eventually undergo surgical resection
of diseased ileum because of stricturing and penetrating complications [11]. Unfortunately,
disease recurrence in previously disease-free segments of the ileum at the surgical anastomosis
is common [12–16]. A reduced relative abundance of Faecalibacterium prausnitzii, a commen-
sal anaerobic bacterium in the distal intestine (ileum and colon), has been a consistent feature
associated with the ileal CD phenotype [1, 3,4,17–21]. This bacterial species, along with other
closely related clostridial species, are key sources of the short chain fatty acid butyrate, which is
the preferred energy source for enterocytes in the distal intestine, and exhibits anti-inflamma-
tory and pro-intestinal barrier properties in experimental mouse models [22]. A diminished
relative abundance of ileal F. prausnitzii at the time of resection has been associated with a
higher risk of post-operative endoscopic recurrence of ileal CD six months after surgery
[17,23–25]. Consequently, an additional goal of this study was to determine whether alter-
ations in the relative abundances of specific bacterial taxa, such as F. prausnitzii, at the time of
ileal resection were predictive of subsequent endoscopic recurrence. To this end, ileal micro-
biota in the disease unaffected region of the ileal resection were compared between a group of
ileal CD subjects who subsequently developed endoscopic recurrence in the neo-terminal
ileum and a group of ileal CD subjects who did not, 6–12 months after initial surgery.
Materials and methods
Patient recruitment
This study was approved by the Institutional Review Boards of Stony Brook University (IRB#
245010), Washington University-St. Louis (IRB# 201101774), and the University of North
Ileal microbiome in ileal Crohn’s disease
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Carolina (IRB# 10–0355). Patient written consents were obtained from all study participants
and assent and parental consents were obtained for children <18 years of age at their respec-
tive institutions. Coded samples stripped of all identifying information were collected from
subjects in the three following categories: 1) Ileal CD patients undergoing initial ileocolic
resection (ICR) of diseased ileum; 2) colitis patients without ileitis (predominantly ulcerative
colitis or UC, but also Crohn’s colitis and indeterminate colitis) undergoing initial total colect-
omy; and 3) patients without IBD undergoing initial right or total colectomy were prospec-
tively enrolled to donate tissue, blood and longitudinal clinical information in a consecutive
fashion by the Stony Brook University GI Biobank (Batch 2, 2010–2012), the Washington Uni-
versity Digestive Diseases Research Core Center Biobank Core (Batch 1, 2005–2010; Batch 2,
2010–2012) and the U. of North Carolina Multidisciplinary IBD Center (Batch 2, 2011–2012)
as previously described [4]. The diagnosis of ileal CD, UC, indeterminate colitis and Crohn’s
colitis was made ultimately on the basis of pathological criteria (surgical resection specimen)
[26–28]. A minimum of 4 ex-vivo biopsies were taken separately from the macroscopically dis-
ease unaffected proximal ileal margin (from all subjects) and from the disease affected region
Table 1. Distribution of NOD2, ATG16L1, IRGM, CARD9 and ORMDL3 risk alleles and clinical characteristics in ileal CD, colitis and non-IBD subjects in batches
1 and 2. The percent of subjects recruited at each of the three IBD centers with complete genotype and clinical characteristics with at least one risk allele and the percent of
subjects who have at least one risk allele (see Methods) are listed.
Ileal CD Colitis Non-IBD
n = 106 n = 88 n = 89
Batch1 Batch2 P value Batch1 Batch2 P value Batch1 Batch2 P value
n = 50 n = 56 n = 59 n = 29 n = 56 n = 33
IBD Center
Wash. U.-St. Louis 100% 62% 100% 83% 100% 73%
Stony Brook U. 0% 9% 0% 17% 0% 27%
U. of North Carolina 0% 29% 0% 0% 0% 0%
IBD Risk Allele
NOD2R composite 40% 30% 0.38 19% 14% 0.78 14% 52% <0.001
ATG16L1R 94% 79% 0.05 81% 76% 0.79 77% 79% 0.99
IRGMR 30% 27% 0.90 29% 17% 0.34 27% 18% 0.38
CARD9R 94% 96% 0.98 93% 93% 1 88% 91% 0.85
XBP1R 12% 14% 0.99 10% 14% 0.84 14% 0% 0.01
ORMDL3R 76% 73% 0.90 75% 79% 0.88 62% 70% 0.51
Clinical covariates
Male gender % 46% 43% 0.91 53% 55% 1 41% 39% 0.99
Caucasian race % 94% 82% 0.11 91% 97% 0.55 89% 94% 0.56
Median age years
(range)
33
(18–72)
32
(17–67)
44
(18–69)
47
(20–72)
61
(24–84)
62
(17–86)
Duration IBD years
(range)
5
(0–38)
5
(0–35)
5
(0–45)
5
(0.1–30)
NA NA
Current smoker % 32% 29% 0.90 10% 3% 0.46 27% 18% 0.38
+ fecal C. difficile toxin % 0% 5% 0.32 24% 0% 0.01 0% 6% 0.23
Colon Cancer % 6% 0% 0.20 17% 3% 0.13 54% 45% 0.46
Median BMI kg/m2
(range)
24
(16–41)
23
(14–44)
26
(16–43)
28
(19–36)
28
(18–47)
26
(20–48)
5-ASA % 60% 38% 0.04 63% 48% 0.27 0% 3% 0.65
Steroids % 48% 54% 0.67 54% 52% 1 2% 12% 0.11
Immunomodulators % 48% 30% 0.09 29% 28% 1 4% 6% 0.98
Anti-TNF alpha % 24% 45% 0.04 31% 52% 0.09 2% 0% 0.96
https://doi.org/10.1371/journal.pone.0213108.t001
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(from ileal CD subjects) of fresh pathological specimens using Radial Jaw4 large capacity
biopsy forceps (Boston Scientific, Natick, MA), and immediately placed in RNA stabilization
solution (RNAlater, Life Technologies, Grand Island, NY, USA) overnight at 4˚C prior to stor-
ing at -80o C. A subset of the ileal CD patients (n = 61) underwent follow up colonoscopy
within 6–12 months to assess endoscopic disease recurrence as previously described [29]. Ex-
vivo research ileal biopsies, blood and longitudinal clinical information were also prospectively
collected from non-IBD patients undergoing colonoscopies for colon cancer screening by the
Stony Brook University GI Biobank (2010–2012) and the Washington University Digestive
Diseases Research Core Center Biobank Core (2005–2012).
Additional clinical metadata on smoking, obesity, and IBD medications were obtained on
samples collected by the Stony Brook University GI Biobank and the Washington University
Digestive Disease Research Core Center Biobank Core and Dr. Sartor’s laboratory, by review-
ing the medical records including the pathology report of the resected intestine by a gastroen-
terologist (EL, RBS) [4]. Preoperative mechanical bowel preparations were not routinely
ordered for surgical procedures on IBD patients but were often ordered for the non-IBD
patients. A smoker was defined as smoking�7 cigarettes a week for at least a year [12,30]. In
order to assess the potentially confounding effect of obesity [31], body mass index (BMI) was
also recorded. C. difficile infection, which has been associated with IBD [32], was recorded as
the presence of a positive fecal C. difficile toxin B [33] within a week of the sample collection.
Antibiotics have a significant effect on the microbiome [34] and all patients received preopera-
tive surgical antibiotic prophylaxis (long-acting beta lactam 30 minutes before the initial inci-
sion was made) [35]. Patients diagnosed with C. difficile infections (predominantly colitis
patients) were treated with oral vancomycin up until surgery. The few non-IBD (total<10)
subjects from whom ileal research biopsies were collected during colonoscopy did not receive
antibiotics prior to collection of the ileal biopsies for at least two months. Dietary information
collected on the subjects revealed that none of the subjects were vegetarian and none of the
subjects were on either elemental or polymeric enteral feedings [34]. Because there was no sig-
nificant difference between the three institutions with respect to race and ethnicity (all pre-
dominantly non-Hispanic White/Caucasian), the Batch 2 patients were analyzed as a single
cohort.
IBD genotyping
Because of their relationship to Crohn’s disease phenotype, our analysis focused on the follow-
ing single nucleotide polymorphisms (SNPs), which are implicated in microbial sensing,
autophagy, endoplasmic reticulum stress, and/or Paneth cell dysfunction [6–10]: 1) NOD2
risk alleles (rs2066847, rs2066884, rs2066845, rs5743289) [9,36–41], ATG16L1 (rs2241880)
[42–45], IRGM (rs13361189) [46–48], 2) CARD9 (rs10870077) [49,50], 3) XBP1 (rs35873774)
[51], 4) ORMDL3 (rs2872507) [52]. The subjects were categorized as 1) homozygous for
both non-risk alleles NR/NR), termed NR or 2) carrying at least one risk allele (R/NR, R/R),
termed R. Four major NOD2 risk alleles were combined to form two composite categories: 1)
NOD2NR, subjects harboring none of the four major risk alleles 2) NOD2R, subjects harboring
at least one of the four major risk alleles (i.e., NOD2R/NR + NOD2R/R). Illumina Immunochip
genotyping using genomic DNA prepared from peripheral blood and/or tissue was performed
on all of the subjects [53–55]. A subset of these patients had previously undergone genotyping
by using the Sequenom MassArray System (Sequenom Inc., San Diego, CA) in the Washing-
ton University Sequenom Technology Core 3]. In the patients for which genotyping of the
three major nonsynonymous NOD2 risk alleles, Leu1007fs (rs2066847, SNP13), R702W
(rs2066884, SNP8) and G908R (rs2066845, SNP12), could not be assigned by Illumina
Ileal microbiome in ileal Crohn’s disease
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Immunochip, genotyping for these SNPs was performed by Taqman Genotyping Assays (Life
Technologies, Grand Island, NY, USA) as previously described [4]. For the ATG16L1 and
IRGM genotypes, the value of a missing SNP was imputed from other tightly linked SNPs. For
ATG16L1 the tightly linked SNP was rs12994997 and for IRGM genotype the SNPs were
rs10065172 and rs11747270.
16S rRNA amplicon library construction and sequencing
Amplicons of the V3-V5 hypervariable regions of the bacterial 16S rRNA gene were sequenced
using the 454 FLX Titanium Sequencing Platform and the same primers employed for charac-
terizing the microbial communities in healthy individuals at different body sites including the
gastrointestinal tract by the Human Microbiome Project [4, 56]. Library construction and
sequencing for Batch 1 samples (2005–2010), was performed at the Genome Institute at Wash-
ington University-St. Louis. Library construction and sequencing for a small subset (n = 15) of
Batch 1 samples and for all the Batch 2 (2010–2012) samples for all subjects recruited was per-
formed in the Frank laboratory (UC Denver) and the sequencing was performed at The Centre
for Applied Genomics at the Hospital for Sick Children in Toronto, Canada following the
same standard operating procedures [4]. The variance in the relative abundances of phyla/sub-
phyla taxa between duplicate libraries sequenced at the two different centers (n = 15) did not
exceed the variance observed for duplicate libraries sequenced at a single center (n = 15). Clini-
cal, genotyping, and sequencing data can be accessed through the dbGAP authorized access
system (Request access to: phs000255.v2). In order to request access to any of the individual-
level datasets within the controlled-access portions of the database, the Principal Investigator
(PI) and the Signing Official (SO) at the investigator’s institution will need to co-sign a request
for data access, which will be reviewed by an NIH Data Access Committee at the appropriate
NIH Institute or Center (https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=login).
Sequence reads were screened for basic quality defects by the software program BARTAB
[57]. All sequences were checked for chimerism with Uchime (usearch6.0.203_i86linux32)
[58] using the Schloss Silva references [59]. The filtered sequences were aligned and classified
with SINA (1.2.11 using the 418,497 bacterial sequences in Silva 115NR99 as reference config-
ured to yield Silva technology [60,61]. Operational taxonomic units (OTUs) at the genera level
were produced by clustering sequences with identical taxonomic assignments. Relative abun-
dances were calculated by dividing OTU counts were normalized between samples by dividing
sequence counts by the total number of high-quality 16S sequences generated per sample to
calculate the average relative abundance values shown in (Table 2). Phylum/subphyla level
OTU tables were generated by collapsing lower level OTUs into higher-level categories corre-
sponding to the categories used previously [4]: 1) Actinobacteria, 2) Bacteroidetes, 3) Firmi-
cutes/Clostridia/Ruminococcaceae (family corresponding to Clostridia Group IV), 4)
Firmicutes/Clostridia/Lachnospiriceae (family corresponding to Clostridia Group XIVa), 5)
Firmicutes/Clostridia/Other, 6) Firmicutes/Bacillus (class), 7) Firmicutes/Other, 8) Proteobac-
teria, and 9) Other taxa.
Quantitative PCR for targeted bacterial subgroups
QPCR assays were performed using established primers for total bacteria (forward, 5’- GTG
STG CAY GGY TGT CGT CA-3’ and reverse 5’- ACG TCR TCC MCA CCT TCC
TC-3’) [62], F. prausnitzii (forward 5’-CCC TTC AGT GCC GCA GT-3’ and reverse
5’-GTC GCA GGA TGT CAA GAC-3’) [63], C. coccoides-E. rectales subgroup (forward,
5’–CGG TAC CTG ACT AAG C-3’and reverse 5’–AGT TT(C/T) ATT CTT GCG
AAC G-3’) [63]. The log2 transformation of the relative abundance of each bacterial
Ileal microbiome in ileal Crohn’s disease
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subgroup was measured by ΔCt = Ct (threshold cycle) total bacteria−Ct subgroup. All assays were
carried out in triplicate and results averaged. Plasmid quantification standards were prepared
from representative clones of the target organisms to insure that the assays were conducted
within the linear range and with similar slopes [64].
Statistical analysis
Patient samples with less than 100 total high-quality 16S rRNA sequence counts were excluded
from the analysis. Alpha diversity indices (i.e., Chao1, Shannon complexity H) were calculated
for each using the software package Explicet (v2.9.4, www.explicet.org) [65]. Beta diversity was
calculated using the adonis function in the R vegan package as previously described [66,67] at
the phylum/subphylum level, family and genus levels. This function uses a non-parametric
multivariate analysis of variance test (PERMANOVA) [68], which was applied using Bray-
Curtis, Morisita-Horn and Jaccard indices as distance measurements [69].
Because over-dispersion is often observed in microbiome sequence count data, negative
binomial regression models [70, 71] were used to analyze the 16S rRNA sequence data. The
OTUs (relative abundance�0.0001 and prevalence�0.01) were grouped primarily at the phy-
lum/subphylum level as described above [4]. To identify taxa with significant differences in rel-
ative abundance between disease affected and disease unaffected regions of the resected ileum
in ileal CD patients undergoing initial ICR, a generalized linear mixed model was used:
logðmijkÞ ¼ bi0k þ b1kPathologyij þ b2kBatchi þ ðlog total countÞij
bi0k ¼ b0k þ bikIfPatient ¼ ig
Yijk � NBðmijk; �kÞ
Here Yijk denotes the OTU k’s observed count for tissue j in patient i with μijk being its mean.
The symbol ϕk is the dispersion parameter for the count of OTU k. The OTU k of patient i is
associated with a random coefficient bik in order to assess paired disease affected and disease
unaffected samples collected from the same patient i. The Batch variable refers to whether
Table 2. Comparison of the relative abundances of phyla/subphyla taxa between the disease unaffected and disease affected regions of resected ileum in ileal CD
subjects undergoing initial ICR. The mean relative abundance ± standard deviation is shown for each bacterial category in Batch 1 (2005–2010) and Batch 2 (2010–2012)
as well as the FDR for respectively macroscopic pathology (disease affected vs. disease unaffected) and the sample batch (Batch 1 Batch 2). A total of 101 disease affected
and 111 disease unaffected samples were analyzed, of which 91 were paired samples.
Disease affected Disease unaffected FDR
Batch 1 Batch 2 Batch 1 Batch 2 Path Batch
Actinobacteria 0.028
±0.055
0.006
±0.011
0.049
±0.088
0.009
±0.016
0.092 <0.001
Bacteroidetes 0.314
±0.272
0.447
±0.255
0.292
±0.273
0.356
±0.278
0.346 0.165
Firmicutes/Clostridia/
Lachnospiraceae
0.166
±0.161
0.172
±0.141
0.127
±0.135
0.148
±0.144
0.071 0.449
Firmicutes/Clostridia/
Ruminococcaceae
0.028
±0.039
0.045
±0.074
0.021
±0.031
0.036
±0.08
0.023 0.473
Firmicutes/Clostridia/
Other
0.059
±0.121
0.056
±0.127
0.058
±0.136
0.061
±0.141
0.631 0.449
Firmicutes/Bacilli 0.124
±0.195
0.051
±0.119
0.149
±0.177)
0.088
±0.177
0.071 <0.001
Proteobacteria 0.158
±0.206
0.146
±0.183
0.197
±0.223
0.204
±0.222
0.026 0.637
https://doi.org/10.1371/journal.pone.0213108.t002
Ileal microbiome in ileal Crohn’s disease
PLOS ONE | https://doi.org/10.1371/journal.pone.0213108 February 28, 2019 6 / 22
samples were collected in Batch 1 (2005–2010) or Batch 2 (2010–2012). The log total count of
each patient sample is considered as an offset.
Negative binomial models were used to identify associations between OTUs and IBD phe-
notype (ileal CD, colitis without ileal disease, and control non-IBD), IBD genotype, and clini-
cal co-variates (see Table 1).
For OTU k, the model is:
Yik � NBðmik; �kÞ
logðmikÞ ¼ b0k þ b1kphenotypei þ SjajkGenotypesij þ Slglkcovariatesil þ b2kBatchi
þinteractionsþ ðlog total countÞi
Yik is the observed counts for subject i on OTU k. The IBD genotypes and covariates in the
model are listed in Table 1. The Batch variable refers to whether samples were collected in Batch
1 (2005–2010) or Batch 2 (2010–2012). The interactions included first-order interactions between
phenotype, genotypes, clinical covariates and Batch. Stepwise variable selection based on Bayesian
information criterion (BIC) was applied to generate the final model. The p value of coefficients in
final model was subject to FDR correction [72], with the FDR threshold set at 0.05.
The relative abundances of F. prausnitzii and C. coccoides-E.rectales measured by qPCR
were analyzed using a permutation-based linear regression model.
Results
Distribution of IBD phenotype, genotype, and clinical covariates in Batch 1
(2005–2010) and Batch 2 (2010–2012) samples
Samples were analyzed from 154 subjects in Batch 2 in addition to the 170 subjects in Batch 1
analyzed in our previous study [4]. Of the 324 total subjects, genotype, and clinical data were
completed for 283 (87%) subjects. The distributions of IBD phenotype, genotype, and clinical
covariates for the 283 of 324 subjects with complete datasets are summarized in Table 1. All of
the Batch 1 samples and the majority (62–83%) of Batch 2 samples were collected at the Wash-
ington University–St. Louis medical center and the remaining subjects (17–38%) were
recruited at the Stony Brook University and University of North Carolina medical centers
(Table 1). At all three institutions, the race and ethnicity of the subjects were predominantly
White/Caucasian. The proportion of subjects for each disease phenotype who had at least one
of the following risk alleles: the NOD2 risk super allele (rs2066847, rs2066884, rs2066845,
rs5743289), the ATG16L1T300A allele (rs2241880), the IRGM risk allele (rs13361189), the
CARD9 risk allele (rs10870077), the XBP1 risk allele (rs35873774), and the ORMDL3 risk
allele (rs2872507) are shown in Table 1. The high proportion of NOD2R non-IBD subjects in
Batch 2 reflects preferential selection of these individuals since our previous analysis indicated
that NOD2 genotype was associated with shifts in ileal microbiome composition, independent
of disease phenotype.
The clinical covariates for Batch 1 and Batch 2 samples (Table 1) revealed that the median
duration of IBD prior to initial surgery was 5 years for both ileal CD and colitis subjects. As
previously noted [4], ileal CD subjects were younger than non-IBD patients, and active smok-
ing was less prevalent in colitis subjects. A higher proportion of the Batch 2 ileal CD and colitis
subjects received anti-TNF alpha biologics at the time of surgery than Batch 1 subjects (See
Table 1). A lower proportion of the Batch 2 colitis subjects had C. difficile infections immedi-
ately prior to surgery than the Batch 1 colitis patients.
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16S rRNA sequencing analysis of ileal CD, colitis and non-IBD samples
A total of 5,739,816 high-quality V3–V5 sequences (median 6024 reads/sample, IQR 2950–
10314) were generated from the ileal specimens in this study. All libraries had a Goods cover-
age of� 95% (median 98%, IQR 97.9–98.8%) at the rarefaction point of 500 sequences. All of
the sequences were binned using an updated pipeline as described in Methods. Greater than
90% of the sequences could be binned into the following eight phylum/subphylum categories:
1) Actinobacteria, 2) Bacteroidetes, 3) Firmicutes/Clostridia/Ruminococcaceae, 4) Firmicutes/
Clostridia/Lachnospiraceae, 5) Firmicutes/Clostridia/Other, 6) Firmicutes/Bacillus, 7) Firmi-
cutes/Other, 8) Proteobacteria, (see Fig 1). The Firmicutes phyla were sub-divided between clas-
ses Clostridia, Bacilli and Firmicutes/Other. The Clostridia taxa were then further subdivided
into Clostridia/Ruminococcaceae and Clostridia/Lachnospiraceae at the family level, corre-
sponding to the Clostridium Group IV and XIVa phylum/subphylum categories designated
when the Batch 1 samples were previously analyzed [4]. The remaining Clostridia OTUs were
grouped as Clostridia/Other.
Because samples were collected from both the macroscopically disease unaffected region
(proximal margin) and the disease affected region of the resected ileum, we first examined the
within-subject differences in microbiota between disease unaffected and affected regions of
the ileum. To this end, a generalized linear mixed effect negative binomial model was used to
measure the effects of pathology (disease affected vs. disease unaffected) as well as sample
batch on ileal microbiota binned at the phyla/subphyla level (see Table 2). The effect of pathol-
ogy was significant for Ruminococcaceae (FDR = 0.023) and Proteobacteria (FDR = 0.026, see
Table 2). As shown in Fig 2 and S1 Table, the mean relative abundance of Proteobacteria was
consistently higher in the disease unaffected regions than the adjacent disease affected regions
from ileal CD subjects.
Fig 1. Phylum/Subphylum comparison of ileum-associated bacterial communities of ileal CD, colitis, and non-
IBD samples. The average relative abundances of 6 of 8 phylum/subphylum bacterial category are shown for
macroscopically disease affected and macroscopically disease unaffected samples, respectively from ileal CD, and from
macroscopically disease unaffected samples from colitis and control subjects. In this figure “Other” includes
Firmicutes/Clostridia/Other, Firmicutes/Other and all remaining taxa.
https://doi.org/10.1371/journal.pone.0213108.g001
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Fig 2. The mean relative abundances of selected phyla/subphyla groups between disease affected ileal samples from
ileal CD subjects, disease unaffected ileal samples from ileal CD subjects and disease unaffected ileal samples from
non-IBD subjects. A. Batch 1; B. Batch 2; C. Batch 1 and Batch 2 combined.
https://doi.org/10.1371/journal.pone.0213108.g002
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No significant differences (p< 0.05) were detected in measures of alpha diversity (complex-
ity measured by Shannon H or richness, measured by Chao1) of the ileal microbiome in ileal
CD, colitis, and non-IBD disease unaffected samples or between disease unaffected and disease
affected ileal CD samples. There were significant differences in beta diversity using three dif-
ferent dissimilarity indices, Bray-Curtis (p< 0.001, Fig 3), Jaccard (p< 0.001), and Morasita-
Horn (p<0.001) of the ileal microbiome in disease unaffected regions between the three phe-
notypes. Furthermore, pairwise comparisons revealed significant differences between all three
phenotypes (see S2 Table). While significant differences were detected for individual phyla/
subphyla categories, particularly Proteobacteria, between disease unaffected and disease
affected ileal CD samples, no significant difference in beta diversity was detected using any
three of the dissimilarity indices.
Integrated analysis of the effect of IBD phenotype, genotype and clinical
covariates on phyla/subphyla bacterial categories
Because significant differences were detected between disease affected and disease unaffected
samples from ileal CD subjects, analysis of the effects of IBD genotype (NOD2, ATG16L1,
IRGM, CARD9, XBP1 and ORMDL3) on each phylum/subphylum category was restricted to
only disease-unaffected samples from the three phenotypes (ileal CD, colitis, and non-IBD).
Integrated analysis of the effects of the three IBD phenotypes, six IBD genotypes, 11 clinical
covariates, sample batch, and all first order interactions, was conducted by building negative
binomial models for each of the eight phyla/subphyla categories, using these factors as predic-
tor variables (see Table 3).
The relative abundance of the Actinobacteria phylum was positively associated with both
ileal CD and colitis phenotype and negatively associated with detection of C. difficile fecal
toxin and anti-TNFα biologic use within 8 weeks of surgery. Significant first order interactions
were observed for C. difficile fecal toxin b�age, C. difficile fecal toxin � current smoker, and
IBD duration � anti-TNFα use.
Fig 3. Principal coordinate analysis (PCoA) conducted on genus-level microbiome data using a dissimilarity
matrix of Bray Curtis scores. The IBD phenotypes are color coded as follows: ileal CD (designated by red circle),
colitis without ileal disease (designated by red triangle), non-IBD (designated by green square). The four largest
dimensions (PC1, PC2, PC3, PC4) are shown and account for 11.8%, 6.5%, 3.3% and 2.9% of the differences,
respectively.
https://doi.org/10.1371/journal.pone.0213108.g003
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Table 3. Negative binomial model results for IBD phenotype, genotype and clinical covariates at the phylum/subphylum level. Variables with significant effects are
bolded.
Actinobacteria Log fold change p -value FDR
Main effects1
ileal CD 2.055 <0.0001 <0.0001
Colitis 1.368 <0.0001 <0.0001
Duration IBD -0.064 <0.0001 <0.0001
Batch -1.194 <0.0001 <0.0001
+ C. difficile fecal toxin -2.878 0.0056 0.0083
Anti TNF alpha -0.889 0.0015 0.0026
Current smoker -0.333 0.1081 0.1179
Age 0.001 0.9801 0.9801
First order interactions
+ C. difficile fecal toxin�Current smoker 2.806 0.0009 0.0017
+ C. difficile fecal toxin �Age 0.530 0.0124 0.0149
Duration IBD � Anti TNF alpha 0.008 0.0064 0.0083
Firmicutes/Clostridia/Lachnospiraceae Log fold change p -value FDR
Main effects
Immunomodulators -0.347 0.0068 0.0068
Firmicutes/Clostridia/Ruminococcaceae Log fold change p -value FDR
Main effects
ileal CD -0.989 0.0001 0.0002
Colitis -0.244 0.2714 0.2714
Age -0.017 0.0030 0.0032
Immunomodulators 1.879 0.0160 0.0224
BMI 0.0282 0.0674 0.0787
First order interactions
Immunomodulators � BMI -0.939 0.0012 0.0027
Firmicutes/Clostridia/Other Log fold change p -value FDR
NOD2R 0.569 0.0028 0.0042
ORMDL3R 0.716 0.0001 0.0003
XBP1R -1.000 0.0001 0.0003
+ C. difficile fecal toxin 1.365 0.0001 0.0003
Steroids 0.606 0.0026 0.0042
Immunomodulators -2.387 0.0027 0.0042
BMI -0.0416 0.0065 0.0081
Colon Cancer -0.0384 0.8703 0.8703
Current smoking -0.3546 0.2724 0.3143
First order interactions
Current smoking � 5-ASA 1.9875 <0.0001 0.0002
Current smoking � Steroids -1.287 0.006 0.0081
Immunomodulators � BMI 0.1074 0.0002 0.0005
Firmicutes/Bacilli Log fold change p-value FDR
Main effects
ileal CD 1.7384 <0.0001 <0.0001
Colitis 1.2696 <0.0001 <0.0001
Batch -0.9925 <0.0001 <0.0001
5-ASA -0.8868 0.0049 0.0057
Steroids -0.3359 0.2659 0.2659
(Continued)
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The relative abundance of the Firmicutes/Clostridia/Lachnospiraceae (Clostridia Group
XIVa) family was negatively associated with immunomodulatory use. The relative abundance
of C. coccoides-E. rectales bacterial group determined by qPCR corresponds roughly to the rela-
tive abundance of the Clostridia/Lachnospiraceae family [4]. Univariate analysis did not detect
a significant difference between NOD2R and NOD2NR ileal CD patients as previously reported
for the Batch 1 samples [4]. A linear regression model (see Table 4) detected a positive associa-
tion with the colitis phenotype. There was a trend towards a negative association between rela-
tive abundance of the C. coccoides-E. rectales group and immunomodulatory use and a
significant association with the immunomodulator � C. difficile fecal toxin first order
interactions.
The relative abundance of the Firmicutes/Clostridia/Ruminococcaceae (Clostridia Group IV)
family was strongly negatively associated with ileal CD phenotype and to a lesser extent with
age, and positively associated with immunomodulator use. A significant first order interaction
was observed for immunomodulators � BMI (see Table 3). At a more granular level, the relative
abundance of the Faecalibacterium genus within the Ruminococcaceae family revealed signifi-
cant negative associations with ileal CD phenotype (FDR = 0.0004) and age (FDR = 0.004),
and significant positive associations with immunomodulatory use (FDR = 0.004) and BMI
(FDR = 0.0006). In addition, a significant first order interaction was observed for immunomod-
ulators � BMI (FDR = 0.0007). The negative association with ileal CD was further confirmed by
Table 3. (Continued)
Actinobacteria Log fold change p -value FDR
First order interactions
5-ASA�Steroids 1.4087 0.0014 0.0019
Proteobacteria Log fold change p-value FDR
Main effects
ileal CD 0.6767 <0.0001 0.0001
Colitis 0.5257 0.002 0.0023
NOD2R -1.0788 0.0002 0.0003
ORMDL3R -0.2539 0.1433 0.1433
First order interactions
NOD2R� ORMDL3R 1.3856 <0.0001 0.0001
https://doi.org/10.1371/journal.pone.0213108.t003
Table 4. Linear regression results for disease phenotype, IBD genotype and additional clinical covariates (see Table 1) and the relative abundance of the C. coc-
coides-E. rectales bacterial subgroup and F. prausnitzii. Log fold change was determined by real time qPCR. Variables with significant effects were bolded.
C. coccoides-E-rectales bacterial subgroup Log fold change p-value FDR
Main effects
ileal CD 0.129 0.772 0.772
Colitis 1.456 0.002 0.004
Immunomodulators -0.762 0.095 0.143
C. difficile fecal toxin -1.08 0.290 0.347
First order interactions
Immunomodulators� C. difficile fecal toxin 4.71 0.001 0.004
Faecalibacterium prausnitzii Log fold change p-value FDR
Main effects
ileal CD -1.691 0.001 0.001
Colitis -0.930 0.074 0.074
https://doi.org/10.1371/journal.pone.0213108.t004
Ileal microbiome in ileal Crohn’s disease
PLOS ONE | https://doi.org/10.1371/journal.pone.0213108 February 28, 2019 12 / 22
measuring the relative abundance of F. prausnitzii by qPCR (FDR = 0.001, see Table 4). In
addition, within the Ruminococcaceae (Clostridia Group IV) family, the relative abundance of
the Subdoligranulum genus was also negative associated with the ileal CD phenotype (FDR<
0.0001) and colitis phenotype (FDR = 0.006).
Multiple associations, including IBD genotype (NOD2R, ORMDL3R, XBP1R), medications
(steroids, immunomodulators), C. difficile fecal toxin and BMI were detected with the relative
abundance of the remaining Clostridia taxa binned as Firmicutes/Clostridia/Other (see
Table 3). Exploratory analyses did not detect associations between these three IBD genotypes
with the predominant families binned within this group, such as Clostridiales/Clostridiaceae or
Clostridiales/Peptostreptococcaceae.
The relative abundance of the Firmicutes/Bacilli class was positively associated with both
ileal CD and colitis phenotype and negatively associated with 5-ASA (see Table 3). A signifi-
cant first order interaction was observed for 5-ASA � Steroids. At a more granular level, similar
associations with ileal CD (FDR = 0.04) and colitis (FDR = 0.02) phenotypes and negatively
associated with 5-ASA (FDR = 0.003) were observed for the Streptococcaceae family, which is
binned within this subphylum.
The relative abundance of the Proteobacteria phylum was positively associated with ileal
CD and colitis phenotypes, but negatively associated with NOD2 genotype (see Table 3). Sig-
nificant first order interactions were observed for NOD2R � ORMDL3R genotype and 5-ASA �
anti-TNFα. Similar associations were observed for the relative abundance of the Pseudomona-
daceae family and ileal CD phenotype (FDR<0.0001) and colitis phenotype (FDR = 0.0006).
A similar association was observed between the relative abundance of the Pseudomonas genus
and ileal CD phenotype (FDR<0.0001). In addition, significant associations were detected
with XBP1R (FDR = 0.0004) and with NOD2R�XBP1R first order interactions (FDR = 0.005).
Although the negative association between relative abundance of the Enterobacteriaceae family
and NOD2Rgenotype did not reach significance (FDR = 0.15, FDR threshold = 0.05), a signifi-
cant association was detected with first order NOD2R � IRGMR interaction. Finally, significant
associations were detected between the Enterobacteriaceae family and ATG16L1R genotype
(FDR = 0.03), 5-ASA (FDR = 0.035), BMI (FDR = 0.001), and 5-ASA � BMI first order interac-
tions (FDR = 0.01).
No significant effects were detected for the relative abundance of the remaining phyla/sub-
phyla categories including the Bacteroidetes phylum.
Microbial biomarkers of post-operative endoscopic recurrence in ileal CD
subjects
Of the 124 ileal CD subjects included in this study, 61 subjects underwent postoperative ileo-
scopy of the neo-terminal ileum 6–12 months after surgery. The distribution of subjects for
each Rutgeerts score were as follows: i0, n = 22; i1, n = 12; i2, n = 15; i3, n = 7; i4, n = 5. There-
fore, 34 ileal CD subjects did not subsequently develop endoscopic recurrence (i0-i1) in the
neo-terminal ileum, whereas the remaining 27 ileal CD subjects did subsequently develop
endoscopic recurrence (i2-i4). Further analyses were conducted to compare the microbial
composition of the disease unaffected region of the resected ileum in the 27 subjects who sub-
sequently developed endoscopic recurrence with that of the 34 subjects who did not.
No difference in alpha- or beta-diversity at the phylum, family, or genus level, was detected
in the disease unaffected specimens collected from the ileal CD subjects who did or did not
subsequently develop recurrence. To identify potential microbial biomarkers of recurrence,
univariate negative binomial analyses were conducted to identify taxa with significant differ-
ences in relative abundances between the ileal CD subjects who did or did not subsequently
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develop recurrence. No significant difference was observed when the bacteria were binned at
the phyla/subphyla level. At the family level, the relative abundance of a number of bacterial
taxa, including two potentially pathogenic families, Pasteurellaceae and Mycobacteriaceae, dif-
fered between ileal CD patients with and without recurrence (see Table 5). However, although
the relative abundance of the Ruminococcaceae family was decreased in ileal CD patients who
subsequently developed endoscopic recurrence compared to those who did not, the difference
did not reach statistical significance. QPCR measurements of the relative abundance of C. Coc-
coides-E. rectales (i.e., members of the Lachnospiraceae family), and F. prausnitzii (i.e., an
abundant species of the Ruminococcaceae family indicated significantly reduced levels of both
taxa in patients with endoscopic recurrence (see Table 4). The difference between the qPCR
and 16S rRNA sequence count data may reflect in part the looser correlation between qPCR
and sequencing compared to the correlation between different sequencing platforms [73].
Discussion
The current studies report findings from an integrative approach to examine the relationships
between host genetic factors, clinical factors, and dysbiosis in an expanded IBD patient dataset
collected from three institutions with approximately double the number of subjects than was
previously reported [4]. This study focused on ileal CD phenotypes and, to reduce heterogene-
ity, included two non-overlapping phenotypes without ileal CD: 1) non-IBD subjects and 2)
colitis subjects without evidence of ileal disease. It is important to note however that the IBD
genotype profiles associated with UC/indeterminate colitis, Crohn’s colitis and ileal CD/ileo-
colonic CD phenotypes represent a continuum [9]. Our analysis emphasizes samples taken
from macroscopically disease-unaffected regions of the ileum, because we detected significant
differences in ileal microbiota between samples obtained from adjacent disease-affected
regions of the ileum, and included only samples from initial ileocolic resections. This is
Table 5. Univariate negative binomial results (p-value and FDR) for endoscopic recurrence: family-level analysis. Only families with FDR corrected p-values<0.05
are included.
Ileal CD p-value FDR
Increased in recurrence Recurrence
Mean ±std
No recurrence
Mean ±std
Proteobacteria/Gammaproteobacteria/
Pasteurellales/Pasteurellaceae
0.0467
±0.1581
0.0173
±0.0664
1E-5 0.002
Proteobacteria/Alphaproteobacteria/
Rhodospirillales/ Acetobacteraceae
0.0005
± 0.1583
0.0000
±0.0001
5E-5 0.004
Firmicutes/Clostridia/Clostridiales/
Other
0.0354
± 0.1405
0.0022
± 0.0046
4E-4 0.016
Actinobacteria/Corynebacteriales/
Mycobacteriaceae
0.0001
±0.0003
0.0000
±0.0003
0.001 0.026
Decreased in recurrence
Proteobacteria/Alphaproteobacteria/
Rhizobiales/ Methylobacteriaceae
0.0092
± 0.023
0.0137
± 0.0505
1E-4 0.006
Proteobacteria/Betaproteobacteria/
Burkholderiales/ Comamonadaceae
0.0028
± 0.0044
0.018
± 0.0663
0.001 0.02
Proteobacteria/Gammaproteobacteria/ Pseudomonadales/Moraxellaceae 0.001
± 0.002
0.0185
± 0.0799
0.001 0.02
Proteobacteria/Betaproteobacteria/
Burkholderiales/ Alcaligenaceae
0.004
±0.005
0.018
± 0.02
0.001 0.02
Firmicutes/Erysipelotrichi/
Erysipelotrichales/Erysipelotrichaceae
0.0001
± 0.0003
0.007
± 0.030
0.002 0.03
https://doi.org/10.1371/journal.pone.0213108.t005
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because increased reflux of colonic content into the neo-terminal ileum, would be anticipated
after surgical removal of the ileocolic valve.
This study linking IBD genotype and clinical covariates to ileal mucosal samples represents
one of the larger patient cohorts and is comparable in size to a previous study, which combined
ileal mucosal biopsies from three institutions in Boston, Toronto and the Netherlands [55].
The V3-V5 pyrosequencing platform used in the current study, differs from the previous study
which utilized the V4 Illumina sequencing [55]. The Illumina sequencing platform is generally
conducted at a greater depth of sequencing (9,55,76–79), however Illumina sequencing read
lengths (V1-V2, V3-V4, V4) are shorter than the pyrosequencing read length (V3-V5),. In the
current study, significant differences in α-diversity were not detected between the three phe-
notypes, possibly because of the lower depth of sequencing using the pyrosequencing
platform.
The dimensions of the linked data sets in the current study were reduced for integrative
analysis by restricting the number of distinct non overlapping IBD phenotypes to 3, binning
the taxa into 8 major phyla/subphyla categories, and by restricting the IBD loci to 6 that have
previously been associated with innate immunity. The analysis was also restricted to macro-
scopically normal appearing disease unaffected ileum at the time of initial surgical resection, in
contrast to the previous study where the ileal samples analyzed were more heterogeneous [55].
Our study is also unique in that detection of fecal C. difficile toxin (primarily in colitis subjects)
was included as a potentially confounding co-variate. The rationale for including this co-vari-
ate is based on our previous study of Batch 1 subjects [4], and a more recent study analyzing
the effect of FMT demonstrated marked dysbiosis associated with recurrent C. difficile infec-
tions in patients with and without ulcerative colitis compared to healthy subjects and com-
pared to ulcerative colitis patients without C. difficile infections [74]. However it remains
difficult to determine whether the marked dysbiosis is related to C. difficile infection or antibi-
otic treatment of the infection.
This expanded study confirmed our previous report [4] linking NOD2R genotype, C. diffi-
cile infection, and IBD phenotype to ileal dysbiosis in Batch1 subjects alone, despite the addi-
tion of four additional genetic loci associated with defects in innate immunity (IRGM,
CARD9, XBP1, and ORMDL3) to the analysis. In our previous study [3], NOD2R genotype
was linked to the relative abundance of the Proteobacteria phylum (p = 0.016, FDR = 0.07)
independent of IBD phenotype. In this current expanded study, this association now reached
significance (FDR = 0.0003). The observation that while ileal CD phenotype is positively asso-
ciated with the relative abundance of Proteobacteria phylum in disease unaffected ileal mucosa,
NOD2R genotype is negatively associated is somewhat puzzling. It may be related to the obser-
vation that the mean relative abundance of Proteobacteria was consistently lower in disease
affected ileal mucosa than in adjacent disease unaffected mucosa in ileal CD subjects. Both
observations reinforce the concept that dysbiosis is detectable in macroscopically normal ileal
mucosa in ileal CD subjects
Aggregate analysis at the phylum/subphylum level could mask the contribution of individ-
ual taxa within each of these groups, particularly if significant associations with phylogeneti-
cally related taxa exhibit opposing polarities. Identifying significant associations with bacterial
subcategories at the family or genus level likely was limited by the reduced relative abundance
of the individual taxa and the increased number of multiple comparisons. We are currently
pursuing deeper sequencing and expanding the patient cohort to increase statistical power to
detect differences in lower-level taxa. Nonetheless, at a more granular level, a possible effect of
NOD2 genotype was detected through NOD2 � XBP1 first order interactions with the relative
abundance of Pseudomonas genus, and through the NOD2�IRGM first order interaction with
the relative abundance of the Enterobacteriaceae family (FDR<0.05). The NOD2�IRGM
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interaction may reflect, at least in part, direct interactions between the IRGM, NOD2, and
ATG16L1 gene products, which have been reported to form a molecular complex that modu-
lates autophagic reactions to microbial products [8]. NOD2R genotype was not significantly
associated with lower Enterobacteriaceae (FDR = 0.15) based on our threshold of FDR = 0.05
in the current study, but the results suggest a trend. In contrast, NOD2 risk dosage has been
previously correlated with higher Enterobacteriaceae (FDR = 0.11, FDR threshold = 0.25) in
ileal samples collected in two of three cohorts in the previous study (Boston and the Nether-
lands, n = 314) [55]. In summary, while both the current and the previous IBD genotype–ileal
microbiota studies [55] detect associations between NOD2 risk alleles and Proteobacteria taxa,
these associations had opposite polarities. This may relate to the analysis of only macroscop-
ically disease unaffected ileal sample obtained from initial ileal resection in three relatively dis-
tinct IBD subphenotypes (ileal CD, colitis and non-IBD) in the current study.
NOD2 and other additional IBD genotypes (ORMDL3, XBP1) were also linked to the rela-
tive abundance of Clostridia spp. not binned into either the Ruminococcaceae or Lachnospira-
ceae families, but we were unable to attribute this association to any of the taxa within this
bacterial category. In the expanded study we could not confirm the increased abundance of C.
coccoides–E. rectales group and F. prausnitzii previously detected by PCR analysis in NOD2R
ileal CD subjects compared to NOD2NR ileal CD subjects in Batch 1 alone [4]
A recent analysis of the effect of NOD2 homozygotes and compound heterozygotes com-
pared to wild type NOD2 homozygotes in CD patients in clinical remission and in non-IBD
controls detected no significant differences in the fecal microbiota [75]. This may be due in
part to the smaller sample size, to the asymptomatic status of the CD patients, and to composi-
tional differences between ileal microbiota and fecal microbiota [76–78].
Associations between ileal CD phenotype were confirmed with the decreased relative abun-
dance of the Ruminococcaceae family and increased relative abundances of the Actinobacteria
phylum and the Firmicutes/Bacillus class. These analyses also confirmed similar associations
between the relative abundances of F. prausntizii within the Ruminococcaceae family, the Cory-
nebacteriaceae family in the Actinobacteria phylum, and the Streptococcaceae family in the
Bacillus class.
The current study has a larger or comparable cohort size compared with previous studies
on microbial predictors of post-ICR endoscopic recurrence at the time of resection [17,22–
25,79]. Q-PCR analysis of F. prausnitzii abundance confirmed that there was reduced abun-
dance of this species in subjects that subsequently went on to develop endoscopic recurrence
at 6–12 months compared to those that did not develop recurrence. In addition exploratory
analysis identified two potentially pathogenic taxa, Pasteurellaceae and Mycobacteriaceae, with
increased abundance in subjects that subsequently developed endoscopic recurrence com-
pared to those that did not. Atypical mycobacteria have been implicated in the pathogenesis of
CD [80]. The abundance of Pasteurellaceae is increased in fecal microbiota collected from
treatment-naïve new-onset CD subjects compared to non-IBD subjects [21]. Somewhat puz-
zling is a report from a recent study [78] that the abundance of Pasteurellaceae is increased in
the resected ileum collected from patients that remain in remission compared to those that
have endoscopic recurrence. It remains to be determined whether the taxa associated with
endoscopic recurrence simply reflect subtle alterations in the local environment, such as
changes in pH or oxidation, or whether they play a causal role in promoting recurrent inflam-
mation in the peri-anastomotic neo-terminal ileum.
Our study likely was limited by the batch effect observed, most notably for the relative
abundance of the Actinobacteria phylum and the Firmicutes/Bacilli class between Batch 1
(2005–2010) and Batch 2 (2010–2012) cohorts. Several differences between the two patient
sample cohorts, Batch 1 and 2, could contribute to this effect. Despite the use of the same
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primers for library construction and the same pyrosequencing platforms, which generated
concordant results in a preliminary duplicate analysis of a small subset of samples, some sys-
tematic technical errors may have contributed to batch effects. Another factor could be related
to demographic differences between Batch 1 and Batch 2 patients, which included a higher
proportion of NOD2R non-IBD patients, a higher proportion of patients treated with anti-
TNFα biologics, and a lower proportion of patients treated with 5-ASA medications in Batch 2
compared to Batch 1 (see Table 1) This study was also limited with respect to assessing the
effect of antibiotics, because all of the patient received antibiotics prior to the collection of the
samples during surgical resection except <10 non IBD subjects, who contributed endoscopic
biopsies in Batch 2, where they received no antibiotics.
In summary, the results of this integrative analysis of a large number of uniformly curated
samples, confirm a significant effect of IBD phenotype, C. difficile infection, and NOD2 geno-
type on ileum-associated microbiota. Furthermore, we present data demonstrating that addi-
tional IBD-related genotypes, specifically alleles of ORMDL3 and XBP1, are associated with
changes in the ileal microbiome at the phyla/subphyla level, particularly Proteobacteria, either
as direct effects or through interactions with NOD2 or other clinical variables. As we continue
to expand our systematic accrual of subjects, further associations between host, environment,
and microbial factors with ileal CD phenotype and clinical outcome will emerge and help
delineate the complex etiology of this disease.
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